Mizuho lowered the firm’s price target on MiMedx (MDXG) to $15 from $16 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- CMS reviewing coverage policies for skin substitute products
- Northland says MiMedx ‘oversold,’ sees ‘compelling buying opportunity’
- MiMedx Group: Strong Sales Performance and Strategic Positioning Support Buy Rating
- MiMedx Earnings Call: Growth Amidst Challenges
- MiMedx Group Reports Strong 2024 Financial Results